Shareholder Alert: The Ademi Firm investigates whether Hologic Inc. is obtaining a Fair Price for its Public Shareholders

Group 1 - Hologic shareholders will receive $76 per share in cash plus a contingent value right of up to $3 per share, with payments contingent on achieving revenue goals for the Breast Health business in fiscal years 2026 and 2027 [2] - The transaction agreement imposes significant penalties on Hologic for accepting competing bids, raising concerns about the board's fiduciary duties to shareholders [3] - The Ademi Firm is investigating potential breaches of fiduciary duty by Hologic's board in relation to the transaction with Blackstone and TPG [1][3]